JHD

JHD Life Sciences is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule drugs targeting epigenetic regulators. The company's research centers on modulating histone-modifying enzymes, such as histone deacetylases (HDACs) and histone demethylases (KDMs), to treat cancer and autoimmune diseases. Its lead candidate, JHD-001, is a potent and selective HDAC inhibitor currently being evaluated in Phase 1 clinical trials for hematological malignancies and solid tumors. JHD Life Sciences leverages a global R&D model with operations in both the United States and China to accelerate its drug discovery programs. The company's pipeline also includes preclinical inhibitors targeting KDM5 and KDM4, aimed at overcoming drug resistance in various oncology indications.